Abstract
Repeated mRNA vaccinations are an efficient tool to combat the SARS-CoV-2 pandemic. High levels of neutralizing SARS-CoV-2-antibodies are an important component of vaccine-induced immunity. Shortly after the first or second mRNA vaccine dose, the IgG response mainly consists of the pro-inflammatory isotypes IgG1 and IgG3 and is driven by T helper (Th) 1 cells. Here, we report that several months after the second vaccination, SARS-CoV-2-specific antibodies were increasingly composed of non-inflammatory IgG2 and particularly IgG4, which were further boosted by a third mRNA vaccination and/or SARS-CoV-2 variant breakthrough infections. While IgG antibodies were affinity matured and of high neutralization capacity, the switch in constant domains caused changes in fragment crystallizable (Fc)-receptor mediated effector functions, including a decreased capacity to facilitate phagocytosis. IgG4 induction was neither induced by Th2 cells nor observed after homologous or heterologous SARS-CoV-2 vaccination with adenoviral vectors. In addition, IgG2- and IgG4-producing memory B cells were phenotypically indistinguishable from IgG1- or IgG3-producing cells. Since Fc-mediated effector functions are critical for antiviral immunity, the described class switch towards non-inflammatory IgG isotypes, which otherwise rarely occurs after vaccination or viral infection, may have consequences for the choice and timing of vaccination regimens using mRNA vaccines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the Bavarian State Ministry for Science and the Arts for the CoVaKo-2021 and For-COVID projects and the German Federal Ministry of Education and Science (BMBF) through the ‘Netzwerk Universitaetsmedizin’, project ‘COVIM’ (to T.H.W. and H.H.). Further support was obtained from faculty COVID-19 fonds and the German Centre for Infection Research (DZIF). K.S. is supported by the BMBF (project 01KI2013) and the Else Kroener-Fresenius-Stiftung (project 2020_EKEA.127). K.K. is supported by the Deutsche Forschungsgemeinschaft (DFG) through the research training group RTG 2504 (project number: 401821119)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the medical faculty of the Friedrich-Alexander Universitat of Erlangen-Nurnberg, Germany, gave ethical approval for this work (Az. 340_21B, Az. 46_21B, 350_20B and 235-18B).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵§ jointly supervised this work
Data Availability
All data produced in the present study are available upon reasonable request to the authors
